Pharmbio wins over Novartis’ Revolade in patent dispute
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.04.22 12:05:01
가나다라
0
Received the patent court, IPTAB, decision to establish its claim…Succeeded in avoiding three formulation patents following SK Plasma
Pharmbio Korea already received a generic BLA, but its product launch date is unclear…May face challenge by Norvartis’ appeal
▲Pharmbio Korea has won the first trial in a patent dispute over Novartis' 'Revolade.'
Pharmbio Korea has won the first trial in a patent dispute against 'Revolade (eltrombopag olamine),' a treatment for primary immune thrombocytopenia (ITP), following SK Plasma.Pharmbio Korea received a generic biological license application (BLA) prior to winning the first trial, but the company may face a high risk in launching the product. It is highly possible that the patent holder, Novartis, will appeal to the verdict.
According to industry sources on the 22nd, the Intellectual Property Trial and Appeal Board (IPTAB) decided on the validity of three Revolade formulation patents brought by Pharmbio Korea against Novartis, issuing a favorable ruling on the claim validity on the 19t
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)